Here is the first podcast of what we plan will be an ongoing series of round table discussions with cancer experts about real case scenarios and how we make decisions in practice.  My guests for the discussion are Drs. Janessa Laskin, medical oncologist from British Columbia Cancer Agency in Vancouver, BC, and Alan Sandler, medical oncologist and Director of Hematology/Oncology at Oregon Health & Science University in Portland.

The first case we discussed is a relatively young Asian never-smoking woman with an advanced lung adenocarcinoma, focusing first on the changing standards for sending tissue for molecular testing, as well as the limitations of that.  Here is the video version, audio, transcript, and associated figures.

round-table-laskin-sandler-never-smoker-mutn-testing-audio-podcast

round-table-laskin-sandler-never-smoker-mutn-testing-transcript

round-table-laskin-sandler-never-smoker-mutn-testing-figures

The case continues with the next podcast, discussing first-line chemotherapy-based treatment options and maintenance therapy.  Look for that next week.

I’ve completed several initial podcasts with colleagues from around the country just over the last few weeks, using largely my own cases.  However, as I mentioned in an earlier post, we are happy to consider your own cases and questions if you would like to submit them and have questions that are timely and potentially relevant to a broad audience in the cancer community.  So if you’re interested, please e-mail a brief synopsis and perhaps your central question(s) to west@cancergrace.org for consideration.

Podcast: Play in new window | Download

Related posts:

Podcast of Webinar by Dr. Lecia Sequist on Acquired Resistance to Oral EGFR Inhibitors A few weeks ago, Dr. Lecia Sequist, Assistant Professor of Medicine at Harvard Medica...

ASCO vs. NCCN: Very Different Views on Molecular Testing in Advanced NSCLC A couple of weeks ago, the American Society of Clinical Oncology (ASCO) release...

Who to Test for an EGFR Mutation or ALK Rearrangement: Filtering Based on TTF-1 Status Thyroid transcription factor-1 (TTF-1) is a protein seen on the surface of thyroi...

Dr. Ross Camidge on ALK Inhibition, Molecular Screening, and Options after XALKORI Continuing with Dr. Ross Camidge as our focus (see yesterday’s post for ...

Challenging Cases in Lung Cancer: Stage IIIA N2 Node-Positive NSCLC, Debatably Resectable As part of the series co-sponsored by GRACE and LUNGevity, challenging cases in lun...